MiMedx Group Inc (NASDAQ: MDXG) is a biologics company that processes and sells placental-tissue allografts and animal-derived wound care products to clinicians treating chronic and hard-to-heal wounds. Revenue is transactional, generated by selling tissue grafts and related products to hospitals, wound care centers, and surgical settings, with distribution through independent sales agents and distributors as well as Group Purchasing Organizations and Integrated Delivery Networks. The company's product portfolio includes EPIFIX, EPICORD, EPICORD Expandable, EPIEFFECT, and AMNIOFIX, with domestic sales accounting for the vast majority of revenue as of the FY2025 10-K filed February 25, 2026. In 2024, the company expanded beyond its historical focus on placental biologics by adding xenograft products, and in 2025 and early 2026 entered agreements with manufacturers of other wound care modalities. The company does not pay cash dividends and carries debt under the Citizens Credit Agreement. EW Healthcare Partners holds a material ownership stake.

Revenue model

Transactional product sales of tissue allografts and wound care biologics to clinicians and healthcare facilities, distributed through independent sales agents, distributors, Group Purchasing Organizations, and Integrated Delivery Networks.

Products and services

Placental allografts (EPIFIX, EPICORD, EPICORD Expandable, EPIEFFECT, AMNIOFIX), xenograft animal-derived wound care products added in 2024, and third-party wound care modalities added via manufacturer agreements in 2025 and early 2026.

Customers and end markets

Clinicians and healthcare providers treating chronic wounds (diabetic foot ulcers, venous leg ulcers), surgical specialties including intestinal surgery, wound care centers, and hospital surgical settings. Customer access through Group Purchasing Organizations and Integrated Delivery Networks.

Value-chain role

Tissue processor and commercial-stage biologics manufacturer distributing finished allograft and xenograft products to end-use clinical settings via direct and independent sales channels.

Geographic exposure

Domestic U.S. sales account for the vast majority of revenue as of the FY2025 filing. International expansion is being pursued, primarily targeting Japan.

Source: SEC 10-K, filed 2026-02-25

Industry: Surgical & Medical Instruments & Apparatus Peers: Aldeyra Therapeutics Inc ALPINE IMMUNE SCIENCES, INC. Biomea Fusion Inc BioXcel Therapeutics Inc CONCERT PHARMACEUTICALS, INC. Foghorn Therapeutics Inc Omega Therapeutics, Inc. Prelude Therapeutics Inc Tyra Biosciences Inc